NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for...
SANTA ANA, Calif., February 19, 2025 — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
View ArticleNKGen Biotech Announces Administration of First Dose of Troculeucel to...
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options. SANTA ANA, Calif., February 21, 2025 — NKGen Biotech, Inc....
View ArticleNKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke...
NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients. SANTA ANA, Calif., March 3, 2025 — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a...
View ArticleNKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC...
• Trading commencing on the OTC Markets on March 5, 2025. • Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants. • NKGen Biotech, Inc. (“NKGen” or the...
View ArticleNKGen Biotech To Present on Potential of Troculeucel for the Treatment of...
SANTA ANA, Calif., March 13, 2025 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech To Present Updated Troculeucel Data at the International...
SANTA ANA, Calif., March 25, 2025 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in...
Moderate Alzheimer’s disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment. After 12 months of treatment, both patients who completed 17...
View ArticleNKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and...
SANTA ANA, Calif., April 14, 2025 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the...
SANTA ANA, Calif., May 7, 2025 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65...
New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in...
View Article